sparfloxacin has been researched along with Lung Diseases, Obstructive in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (100.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Allegra, L; Guyen, JN; Hosie, J; Konietzko, N; Leophonte, P; Pauwels, R; Petitpretz, P | 1 |
| Rubinstein, E | 1 |
2 trial(s) available for sparfloxacin and Lung Diseases, Obstructive
| Article | Year |
|---|---|
Comparative safety and efficacy of sparfloxacin in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a double-blind, randomised, parallel, multicentre study.
Topics: Acute Disease; Amoxicillin; Amoxicillin-Potassium Clavulanate Combination; Anti-Infective Agents; Clavulanic Acids; Double-Blind Method; Drug Therapy, Combination; Fluoroquinolones; Haemophilus influenzae; Humans; Lung Diseases, Obstructive; Middle Aged; Moraxella catarrhalis; Quinolones; Streptococcus pneumoniae | 1996 |
Safety profile of sparfloxacin in the treatment of respiratory tract infections.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Clinical Trials, Phase III as Topic; Community-Acquired Infections; Drug Administration Schedule; Female; Fluoroquinolones; Humans; Lung Diseases, Obstructive; Male; Middle Aged; Pneumonia, Bacterial; Quinolones; Randomized Controlled Trials as Topic; Respiratory Tract Infections | 1996 |